Business Wire

CSC Finds Majority of World’s Largest Companies Susceptible to Phishing and Brand Abuse Due to Improper Domain Security

28.9.2021 16:00:00 EEST | Business Wire | Press release

Share

CSC, a world leader in business, legal, tax, and domain security, today released its annual Domain Security Report: Forbes Global 2000 Companies , which found that despite the shift to modernize business environments and operations among the Global 2000 companies, web domains remain dangerously under protected.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005027/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Key findings from the 2021 Domain Security Report (Graphic: Business Wire)

CSC’s research also shows that most Global 2000 companies continue to lag in the adoption of domain security measures. Most notably, 81% of companies are not using registry locks. Other concerning findings illustrate that domain security remains an afterthought for many brands:

  • 70% of homoglyph (fuzzy match) domains—a tactic commonly used in phishing and brand abuse—are owned by third parties
  • 57% of the Global 2000 are relying on off-the-shelf consumer-grade registrars who offer limited domain security mechanisms to protect against domain and DNS hijacking

“Basic domain security measures continue to get overlooked because they’re still not considered an essential component to a company’s broader phishing, business email compromise, or ransomware mitigation approach,” said Mark Calandra, president of CSC Digital Brand Services. “A focus on securing legitimate domains while monitoring for malicious domains in parallel needs to be a bigger priority for companies to stay protected and thwart cyber risk. Otherwise, companies are exposing themselves to significant threats to their cyber security posture, data protection, intellectual property, supply chains, consumer safety, revenue, and reputation.”

CSC’s additional findings leave little doubt that bad actors are applying tactics to hide their tracks and accelerate their attempts to execute their attacks. The research found that among the 70% of third-party domains deemed suspicious:

  • 77% used domain privacy services or also had WHOIS details redacted
  • 43% are configured with MX email records, giving them the ability to send phishing emails
  • 56% were pointing to advertising, pay-per-click content, or being used for domain parking
  • 38% had inactive web content
  • 6% were pointing to brand impersonation and malicious content including phishing and potential malware delivery

The rise of cyber crime and digital fraud, along with a steady increase in domain registrations over the last 18 months, necessitates more industry oversight. At the same time, it’s imperative that companies get proactive with their domain security moving forward. Including security measures can help mitigate phishing—a common starting point in most ransomware attacks. Companies need to take a more aggressive cyber security approach to disrupt criminal activities taking place across their domain ecosystem.

Download the report now at cscdbs.com/securityreport .

To learn more about CSC’s approach to domain security, visit cscdbs.com.

About CSC

CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® for enterprise domain names, domain name system, and digital certificate management, as well as digital brand, fraud, and phishing protection. We secure companies against cyber threats to their online assets using our proprietary security solutions, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties. We also provide a combination of online brand monitoring and enforcement, taking a holistic approach to digital asset protection. Learn more about our domain management, security, brand protection, and fraud protection services at cscdbs.com.

Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Steve Bosk
W2 Communications
215-378-1056
CSC@w2comm.com
CSC Newsroom

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 202620.10.2026 16:02:00 EEST | Press release

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The studies span Guardant's cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. Significant studies were conducted independently by industry collaborators, academic institutions, and Guardant’s public-private partners using the company’s technologies and/or real-world data, underscoring the wide adoption of its platform across the research community. “At ESMO, we will showcase how InfinityAI is advancing our portfolio, strengthening the clinic

First Cessna Citation CJ4 Gen3 Advances Toward Entry Into Service as First Production Unit Rolls out of the Factory20.10.2026 16:00:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, recently celebrated the rollout of the first production unit of the Cessna Citation CJ4 Gen3, an important milestone as the aircraft advances toward entry into service. The rollout represents Textron Aviation's continued investment in the light jet lineup, bringing Garmin G3000 PRIME avionics, Garmin Emergency Autoland and other customer-driven enhancements to the proven Citation CJ4 platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020982419/en/ First Cessna Citation CJ4 Gen3 advances toward entry into service as first production unit rolls out of the factory. (Photo credit: Textron Aviation) “This rollout is a visible result of the care, precision and teamwork that move an aircraft from design intent to a production-ready airplane,” said Eric Cardinali, senior vice president, Manufacturing Operations. “For our manufacturing teams, it represents the discipl

ARIS Launches Process Context for Enterprise AI, Reinforcing Position as the Essential Platform for AI Ecosystem20.10.2026 15:00:00 EEST | Press release

ARIS, the pioneer in business process management whose powerful Enterprise Model has been the foundation for enterprise operations for more than three decades, today launched Process Context for Enterprise AI – to become the critical base layer for the agentic ecosystem, giving agents and applications the business understanding they need to deliver measurable new value. While Process Context is becoming critical for successfully deploying and scaling enterprise AI, it demands far more than simply connecting AI agents to business data. It requires a comprehensive foundation that captures the relationships between processes, people, systems, risks and controls. Built on a comprehensive Digital Twin of the Organization that connects how work is designed with the execution data that sits around it, ARIS provides this critical layer of Process Context from more than 30 years of enterprise knowledge and experience, something new entrants to the space are struggling to replicate. The importan

Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation20.10.2026 15:00:00 EEST | Press release

Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020837126/en/ Hologic and Inpeco S.A. announce a co-marketing partnership for Inpeco's automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab X‘s open automation capabilities, laboratories can achieve high-throughput workflows with the potential to increase sample volumes1 and enhance end-to-end sample traceability2, supporting reliable test results for optimal patient outcomes.3 The Panther System will i

Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma20.10.2026 15:00:00 EEST | Press release

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase 1/Phase 2 clinical updates at the European Society for Medical Oncology (ESMO) Congress (Madrid, Spain, 23-27 October). During the event, Debiopharm will highlight clinical updates on its pipeline targeting the DNA Damage Response (DDR), featuring single-agent data on zedoresertib (Debio 0123) as well as rational combination strategies, with both temozolomide in glioblastoma and with lunresertib (Debio2513) in solid tumors. Debiopharm’s planned activities at ESMO 2026 include: Rapid Oral Presentation (Debio 0123-GBM-105 / NCT05765812): Presenting dose escalation data evaluating zedoresertib in combination with temozolomide in patients with recurrent or progressive glioblastoma. Poster Presentation (Debio 0123-102 / NCT05109975): Presenting Phase 1 expansion data evaluating s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye